Alliance Foundation Trials

71 total trials 61 currently recruiting 2 completed

Trial Pipeline

RECRUITING Phase 2

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

NCT07149363

RECRUITING NA

Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer

NCT06963723

RECRUITING Phase 1

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

NCT04486352

ACTIVE NOT RECRUITING Phase 2

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

NCT05798663

ACTIVE NOT RECRUITING Phase 2

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

NCT04335682

ACTIVE NOT RECRUITING Phase 2

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

NCT04062708

ACTIVE NOT RECRUITING Phase 2

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

NCT04009109

ACTIVE NOT RECRUITING Phase 2

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

NCT03478514

ACTIVE NOT RECRUITING Phase 3

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

NCT02947685

ACTIVE NOT RECRUITING NA

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS

NCT02926911

ACTIVE NOT RECRUITING Phase 3

PALbociclib CoLlaborative Adjuvant Study

NCT02513394

COMPLETED Phase 1

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT03702725

COMPLETED NA

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02744092

What the Pipeline for Alliance Foundation Trials Shows

According to the ClinicalTrials.gov registry, Alliance Foundation Trials is linked to 71 US clinical trials across every stage of research activity. Of those, 61 studies are currently recruiting — about 86% of the sponsor's indexed portfolio — and 2 are already marked complete, representing roughly 3% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Alliance Foundation Trials reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 39 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Alliance Foundation Trials is Blood Clot with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial